These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

755 related items for PubMed ID: 32592688

  • 1. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J, Hamze M, Valton J, Smith J, Djuretic I, Chaparro-Riggers J, Sasu BJ.
    Mol Ther; 2020 Oct 07; 28(10):2237-2251. PubMed ID: 32592688
    [Abstract] [Full Text] [Related]

  • 2. CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.
    Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M.
    Leukemia; 2018 May 07; 32(5):1168-1179. PubMed ID: 29472720
    [Abstract] [Full Text] [Related]

  • 3. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
    Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nuñez N, Simonis A, Pfister S, Wilk CM, McHugh D, Friemel J, Müller AM, Becher B, Münz C, van den Broek M, Neri D, Manz MG.
    Leukemia; 2020 Oct 07; 34(10):2688-2703. PubMed ID: 32358567
    [Abstract] [Full Text] [Related]

  • 4. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
    Wang Y, Xu Y, Li S, Liu J, Xing Y, Xing H, Tian Z, Tang K, Rao Q, Wang M, Wang J.
    J Hematol Oncol; 2018 May 02; 11(1):60. PubMed ID: 29716633
    [Abstract] [Full Text] [Related]

  • 5. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia.
    Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ.
    Haematologica; 2023 Feb 01; 108(2):457-471. PubMed ID: 35950535
    [Abstract] [Full Text] [Related]

  • 6. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 7. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
    Yeung YA, Krishnamoorthy V, Dettling D, Sommer C, Poulsen K, Ni I, Pham A, Chen W, Liao-Chan S, Lindquist K, Chin SM, Chunyk AG, Hu W, Sasu B, Chaparro-Riggers J, Djuretic I.
    Mol Ther; 2020 Mar 04; 28(3):889-900. PubMed ID: 31981494
    [Abstract] [Full Text] [Related]

  • 8. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S, Waldmann A, Billmeier A, Röder J, Lindner A, Ullrich E, Marschalek R, Dotti G, Jung G, Große-Hovest L, Oberoi P, Bader P, Wels WS.
    Int J Cancer; 2019 Oct 01; 145(7):1935-1945. PubMed ID: 30860598
    [Abstract] [Full Text] [Related]

  • 9. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C, Boldajipour B, Kuo TC, Bentley T, Sutton J, Chen A, Geng T, Dong H, Galetto R, Valton J, Pertel T, Juillerat A, Gariboldi A, Pascua E, Brown C, Chin SM, Sai T, Ni Y, Duchateau P, Smith J, Rajpal A, Van Blarcom T, Chaparro-Riggers J, Sasu BJ.
    Mol Ther; 2019 Jun 05; 27(6):1126-1138. PubMed ID: 31005597
    [Abstract] [Full Text] [Related]

  • 10. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia.
    Mansour AG, Teng KY, Li Z, Zhu Z, Chen H, Tian L, Ali A, Zhang J, Lu T, Ma S, Lin CM, Caligiuri MA, Yu J.
    Blood Adv; 2023 Oct 24; 7(20):6225-6239. PubMed ID: 37379267
    [Abstract] [Full Text] [Related]

  • 11. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ.
    J Immunother Cancer; 2021 Sep 24; 9(9):. PubMed ID: 34531250
    [Abstract] [Full Text] [Related]

  • 12. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.
    Sedloev D, Chen Q, Unglaub JM, Schanda N, Hao Y, Besiridou E, Neuber B, Schmitt A, Raffel S, Liu Y, Janssen M, Müller-Tidow C, Schmitt M, Sauer T.
    J Hematol Oncol; 2024 Sep 16; 17(1):85. PubMed ID: 39285441
    [Abstract] [Full Text] [Related]

  • 13. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
    Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK.
    Mol Ther; 2017 Sep 06; 25(9):2202-2213. PubMed ID: 28676343
    [Abstract] [Full Text] [Related]

  • 14. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS.
    Int J Mol Sci; 2017 Oct 27; 18(11):. PubMed ID: 29077054
    [Abstract] [Full Text] [Related]

  • 15. A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.
    Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH, Huang YX.
    Mol Cancer; 2022 Mar 04; 21(1):66. PubMed ID: 35246156
    [Abstract] [Full Text] [Related]

  • 16. Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models.
    Maiorova V, Mollaev MD, Vikhreva P, Chudakov DM, Kibardin A, Maschan MA, Larin S.
    Int J Mol Sci; 2023 Apr 21; 24(8):. PubMed ID: 37108788
    [Abstract] [Full Text] [Related]

  • 17. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo.
    He H, Vedia RA, Lu S, Li Q, Cox KR, St John L, Sergeeva A, Clise-Dwyer K, Alatrash G, Shpall EJ, Ma Q, Molldrem JJ.
    Cytotherapy; 2024 Nov 21; 26(11):1331-1340. PubMed ID: 39033444
    [Abstract] [Full Text] [Related]

  • 18. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M, Wang J.
    Hum Gene Ther; 2018 May 21; 29(5):626-639. PubMed ID: 29409351
    [Abstract] [Full Text] [Related]

  • 19. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G.
    Clin Cancer Res; 2021 Jun 01; 27(11):3141-3153. PubMed ID: 33531429
    [Abstract] [Full Text] [Related]

  • 20. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
    Tang L, Huang H, Tang Y, Li Q, Wang J, Li D, Zhong Z, Zou P, You Y, Cao Y, Kong Y, Guo A, Zhou S, Li H, Meng F, Xiao Y, Zhu X.
    Clin Transl Med; 2022 Sep 01; 12(9):e1043. PubMed ID: 36163632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.